The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.

The present disclosure provides pharmaceutical compositions of niclosamide and a protein that may be administered via inhalation These compositions may be used in nebulized, nasal, and inhaler formats. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer.

The present invention relates to a method for preventing and treating tissue and organ fibrosis, comprising administering an effective amount of plasminogen to a subject.

The present invention relates to a method for preventing atherosclerosis, comprising administeringh a prophylactically effective amount of plasminogen to a subject susceptible to atherosclerosis. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture and a kit comprising plasminogen which are useful for preventing atherosclerosis.

The present invention relates a method for preventing and/or treating a renal tissue injury in a subject, comprising administering an effective amount of plasminogen to the subject, wherein the subject has a risk of the renal tissue injury, is suspected of having the renal tissue injury or suffers from the renal tissue injury. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating a renal tissue injury and its related conditions in a subject.

The present invention relates to a method for preventing and/or treating hyperlipemia and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject susceptible to hyperlipemia, suffers from hyperlipemia or other diseases accompanied by hyperlipemia. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating hyperlipemia and its related conditions in a subject.

Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

The present invention provides a process for the production of human plasminogen starting from human plasma or a fractionation intermediate thereof. The main stages of the process are: a step of virus inactivation, in which human plasma is contacted with a solvent/detergent mixture, a single affinity chromatographic step and a virus removal nanofiltration step. This process is scalable up to industrial level and it provides, without adding any protease inhibitor, a functional and intact finished product suitable to be administered for the treatment of human diseases due to genetic plasminogen deficiency.

The present invention relates to a method for preventing and/or treating a drug-induced renal tissue injury and its related conditions in a subject, comprising administering an effective amount of plasminogen to the subject. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating a drug-induced renal tissue injury and its related conditions in a subject.